Enanta Pharmaceuticals Inc (ENTA) : Eqis Capital Management reduced its stake in Enanta Pharmaceuticals Inc by 2.49% during the most recent quarter end. The investment management company now holds a total of 44,871 shares of Enanta Pharmaceuticals Inc which is valued at $1,181,453 after selling 1,144 shares in Enanta Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Oct 4, 2016.Enanta Pharmaceuticals Inc makes up approximately 0.07% of Eqis Capital Management’s portfolio.
Enanta Pharmaceuticals Inc closed down -0.1 points or -0.38% at $26.47 with 2,57,126 shares getting traded on Tuesday. Post opening the session at $26.52, the shares hit an intraday low of $25.95 and an intraday high of $26.74 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Enanta Pharmaceuticals Inc reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.09. The company had revenue of $14.00 million for the quarter, compared to analysts expectations of $13.95 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 EPS.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.